AUG 15, 2018 1:35 AM PDT

Experimental Drug May Treat The Chronic Itch

WRITTEN BY: Nouran Amin

Investigators at the University of Zurich have discovered a new approach that treats the chronic itch thanks to two receptors in the spinal cord and the right experimental drug.

Through a series of experiments in animal models, researchers were successful in alleviating different forms of acute as well as chronic itch. The drug serves especially useful for treating chronic itch since current treatment options are limited.

Itching can occur from many factors. For one, itching can be caused by the unpleasant feeling of being bitten by a mosquito. This type of itch is luckily treated by multiple OTC drugs as well as prescriptions. However, these particular drugs cannot effectively treat the debilitating itch that is caused by patients suffering from skin, kidney, or liver diseases. This particular chronic itch condition, affecting roughly 10 percent of the population, is currently managed with antidepressants or immune suppressants. Once again, these drugs were created to treat other diseases but often fail to be effective in providing the desired relief or come with negative side effects.

Image Retrieved From Unsplash, www.unsplash.com

Hanns Ulrich Zeilhofer, a professor at the Institute of Pharmacology and Toxicology of the University of Zurich, and his research team have now discovered a new way to alleviate the itching sensation. The researchers used an experimental drug to boost the effect of certain neurons present in the spine that block the itch signals from being sent to the brain. The scientists had also previously pinned and described these particular neurons three years ago. Since then, genetic mouse models were used to identify two specific receptors that control the effect of the spinal neurons. These receptors are considered part of a larger group of receptors that are activated by the amino acid transmitter gamma-aminobutyric acid, or GABA. Furthermore, the studied experimental drug was originally developed to treat anxiety through interactions with the two identified receptors. In the experiments, the researchers were able to show that the drug not only suppressed acute itch, but it effectively suppressed against the chronic itch. Mouse models that were treated with the drug were less inclined to scratch themselves and their skin changes healed more efficiently than the animal models administered the placebo. Most importantly, the drug did not cause and any adverse side-effects. "We are confident that the substance we've tested will also be effective in humans,” says Zeilhofer. “At the same time, the findings should be very valuable for veterinary medicine, since: Like humans, dogs also often suffer from the chronic itch. They too, therefore, stand to benefit from the approach."

 

Story Source: Nature Communications, University of Zurich

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
Vaccine Causes More Polio Cases than Wild Virus
The World Health Organization (WHO) has confirmed that 11 new cases of polio in five African countries including Nigeria, Congo and Angola were caused by a...
DEC 02, 2019
Drug Discovery & Development
DEC 02, 2019
New Ultrasound Treatment for Parkinson's Tremors
A non-invasive ultrasound procedure may provide lasting relief from tremors in people with Parkinson’s disease (PD) and essential tremor (ET), accord...
DEC 06, 2019
Microbiology
DEC 06, 2019
Hybrid Antibiotic Can Destroy Dangerous Staph Biofilms
When staph begins to grow on medical devices like implants used on wounds, artificial joints, or catheters, they can cause chronic, serious infections....
DEC 19, 2019
Drug Discovery & Development
DEC 19, 2019
Upcoming Psychedelic Cure for Addiction Derived from African Shrub
Every year, almost 70,000 people die from an overdose in the US. Now, a company called MindMed is testing a compound derived from ibogaine, a West African ...
JAN 16, 2020
Drug Discovery & Development
JAN 16, 2020
Fatty Acid Supplement Repairs Brain After Stroke in Mice
Researchers have found that supplements containing short chain fatty acids (SCFAs) may be able to help the brain recover from having a stroke. This comes a...
FEB 24, 2020
Drug Discovery & Development
FEB 24, 2020
Leukemic Drugs May Target Lung Cancer
Two approved therapeutics for treating leukemia are currently being investigated for treatment-resistant lung cancer.  The findings were based on a li...
Loading Comments...